Do PCSK9 inhibitors reduce cardiovascular events

Do proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors decrease cardiovascular disease (CVD) events. If so, are they cost-effective? For patients with CVD taking maximally tolerated statins, adding evolocumab or alirocumab decreases new CVD events for an additional 1 in 65 patients